SHPAX — Saratoga Health & Biotechnology Portfolio
Data updated: 2026-07-24
SHPAX — Saratoga Health & Biotechnology Portfolio data: holdings, portfolio allocation, expenses, performance, cashflows, risk and SEC filings. United States Health Care Equity · $10.48M AUM · 3.00% expense ratio · 18.7% 1-yr return. From SEC regulatory filings.
SHPAX Fund Overview
SHPAX — Saratoga Health & Biotechnology Portfolio is a US mutual fund managed by Saratoga Advantage Trust, categorised as United States Health Care Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US mutual fund
- Manager: Saratoga Advantage Trust
- Category: United States Health Care Equity
- Assets under management: $10.48M
- 1-year return: 18.7%
- Ticker: SHPAX
- SEC CIK: 0000924628
- SEC series ID: S000010884
- Share class ID: C000030154
SHPAX Holdings
Top 10 holdings of Saratoga Health & Biotechnology Portfolio by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| Cardinal Health, Inc. | 6.44% |
| Jazz Pharmaceuticals PLC | 6.19% |
| United Therapeutics Corp. | 6.17% |
| Amgen, Inc. | 5.04% |
| Mckesson Corp. | 4.90% |
| Lantheus Holdings, Inc. | 4.64% |
| Exelixis, Inc. | 4.55% |
| Novartis AG | 4.50% |
| Cencora, Inc. | 4.33% |
| Gilead Sciences, Inc. | 3.94% |
SHPAX Portfolio Allocation
Asset-class allocation of Saratoga Health & Biotechnology Portfolio by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 99.0% |
| Cash & Equivalents | 1.6% |
SHPAX Performance
Total returns for SHPAX (as of 2026-08-01), from SEC filings.
| Period | Total return |
|---|---|
| YTD | 6.3% |
| 1 year | 18.7% |
| 3 years (annualised) | 10.2% |
| 5 years (annualised) | 8.3% |
SHPAX Risk Information
Risk metrics for SHPAX, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 13.3%
SHPAX Costs and Fees
SHPAX costs about $300 per $10,000 invested per year in fund expenses.
- Net expense ratio: 3.00%
- Gross expense ratio: 3.00%
- Portfolio turnover: 22%
- Brokerage commissions: 1.87 bps of average net assets (SEC N-CEN)
SHPAX Cashflows
Over the 12 months to 2026-02, Saratoga Health & Biotechnology Portfolio had net outflows of $725.28K, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2026-02 | −$106.21K |
| 2026-01 | −$161.29K |
| 2025-12 | $358.18K |
| 2025-11 | −$22.69K |
| 2025-10 | −$59.98K |
| 2025-09 | −$107.25K |
SHPAX Debt Constituents
No individual debt constituents are reported in Saratoga Health & Biotechnology Portfolio's latest SEC N-PORT filing.
SHPAX Prospectus and SEC Filings
Official Saratoga Health & Biotechnology Portfolio filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
Related Funds
Other United States Health Care Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.